Search
for
Sort by
Research 181–210 of 777
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
- Alopecia Areata: Current Review
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Baricitinib: A Review in Severe Alopecia Areata
- JAK inhibitors in dermatology: The promise of a new drug class
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- JAK Inhibitors for Treatment of Alopecia Areata
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- Could baricitinib treat frontal fibrosing alopecia and facial papules?
- Baricitinib as a treatment for myasthenia gravis: A case report
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib